Get the Stockscreener App
3.01
1.69%
0.05
After Hours:
3.03
0.02
+0.66%
Recursion Pharmaceuticals Inc stock is traded at $3.01, with a volume of 21.66M.
It is up +1.69% in the last 24 hours and down -14.49% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
See More
Previous Close:
$2.96
Open:
$3.03
24h Volume:
21.66M
Relative Volume:
1.10
Market Cap:
$1.60B
Revenue:
$66.41M
Net Income/Loss:
$-559.78M
P/E Ratio:
-2.5037
EPS:
-1.2022
Net Cash Flow:
$-328.09M
1W Performance:
+4.15%
1M Performance:
-14.49%
6M Performance:
-34.57%
1Y Performance:
-53.62%
1-Day Range:
$2.99
$3.13
1-Week Range:
$2.90
$3.13
52-Week Range:
$2.77
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.01 | 1.57B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
RXRX (RXRX) insider details 50,000-share planned sale and recent stock trades - Stock Titan
RXRX|Recursion Pharmaceuticals Inc|Price:3.030| - TradingKey
Recursion Pharmaceuticals Inc (RXRX) Cash Flow - TradingKey
AI Stocks: Why Tempus AI (NASDAQ:TEM), Recursion Pharmaceuticals (NASDAQ:RXRX) and Schrodinger (NASDAQ:SDGR) Are in Focus - Kalkine Media
TradingKey - TradingKey
Recursion Pharmaceuticals Stock (RXRX) Opinions on Trading Ranges and Biotech Prospects - Quiver Quantitative
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Recursion Pharmaceuticals Inc (RXRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Recursion Pharmaceuticals, Inc (RXRX) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Recursion Pharmaceuticals Inc (RXRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Recursion Pharmaceuticals Inc (RXRX) Institutional Confidence - TradingKey
RXRX|Recursion Pharmaceuticals Inc|Price:2.995|Chg%:-0.015 - TradingKey
Recursion Pharmaceuticals, Inc. (RXRX) Options Chain - Yahoo! Finance Canada
Recursion Pharmaceuticals Inc (RXRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Recursion Pharmaceuticals (RXRX) Proxy filing Summary - Quartr
Recursion Pharmaceuticals (RXRX) Guggenheim Securities 2nd Annual Healthcare Innovation Conference summary - Quartr
RXRX|Recursion Pharmaceuticals Inc|Price:3.030|Chg%:+0.020 - TradingKey
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Recursion Pharmaceuticals Stock Short Interest Falls to 34.41% - Quiver Quantitative
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Exploring a 150% Upside Potential in Biotechnology - DirectorsTalk Interviews
RXRX: Recursion Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Form 144 RECURSION PHARMACEUTICALS For: 17 July By Investing.com - Investing.com Canada
Form 144 RECURSION PHARMACEUTICALS For: 16 July By Investing.com - Investing.com Nigeria
RXRX Stock Slips Onto Watchlists After Insider Form 144 - timothysykes.com
RXRX Stock Under Pressure As Insider Signals Share Sale - StocksToTrade
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today - Yahoo Finance
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy? - The Globe and Mail
Form 144 RECURSION PHARMACEUTICALS For: 13 July By Investing.com - Investing.com Australia
Price to sales forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Price to book forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Enterprise value to revenue forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Price to earnings forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Recursion Pharmaceuticals (RXRX) Highlights Clinical Progress, Is The Stock Fully Priced? - Sahm
2 Beaten-Down Stocks That Still Aren't Worth Buying - The Motley Fool
2 Beaten-Down Stocks That Still Aren't Worth Buying - The Motley Fool
Recursion Pharmaceuticals Stock (RXRX) Opinions on Biotech AI Prospects - Moomoo
Form 144 RECURSION PHARMACEUTICALS For: 10 July By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals (RXRX) Goldman Sachs 46th Annual Global Healthcare Conference 2025 summary - Quartr
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake - Moomoo
Insider Sell: Blake Borgeson Sells 40,000 Shares of Recursion Ph - GuruFocus
Form 4 Recursion Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals director Borgeson sells $158,500 stock By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals director Borgeson sells $158,500 stock - Investing.com
Recursion Pharmaceuticals (RXRX) director sells 40,000 shares in 10b5-1 trade - Stock Titan
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):